Moderna, Inc. (MRNA) Financial Ratios

Moderna, Inc. (MRNA) has an ST Score of 47.6 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate MRNA a Hold, with a price target of $117.40 (-51.5% vs the current price). Our ST Score grades it C+ (47.6/100). The ST Score is a data-driven signal, not a recommendation.

Valuation C, Profitability B, Financial Strength D-, Momentum A, Growth C-, Forecast C, Sentiment A+.

Moderna, Inc. (MRNA) earns a valuation grade of C, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Moderna, Inc. (MRNA) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Moderna, Inc. (MRNA) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Moderna, Inc. (MRNA) earns a financial strength grade of D-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Moderna, Inc. (MRNA) is $117.40 from 29 analysts, which is -51.5% versus the recent price of $242.08.

Moderna, Inc. (MRNA) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.